13 research outputs found

    Production Level CFD Code Acceleration for Hybrid Many-Core Architectures

    Get PDF
    In this work, a novel graphics processing unit (GPU) distributed sharing model for hybrid many-core architectures is introduced and employed in the acceleration of a production-level computational fluid dynamics (CFD) code. The latest generation graphics hardware allows multiple processor cores to simultaneously share a single GPU through concurrent kernel execution. This feature has allowed the NASA FUN3D code to be accelerated in parallel with up to four processor cores sharing a single GPU. For codes to scale and fully use resources on these and the next generation machines, codes will need to employ some type of GPU sharing model, as presented in this work. Findings include the effects of GPU sharing on overall performance. A discussion of the inherent challenges that parallel unstructured CFD codes face in accelerator-based computing environments is included, with considerations for future generation architectures. This work was completed by the author in August 2010, and reflects the analysis and results of the time

    Lack of an Association between a Newly Identified Promoter Polymorphism (-1702G > A) of the Leukotriene C4 Synthase Gene and Aspirin-Intolerant Asthma in a Korean Population

    No full text

    New targets for allergic rhinitis--a disease of civilization

    No full text
    Allergic rhinitis is an inflammatory disorder of the nasal mucosa, mediated by TH2 lymphocytes, which is linked to atopy and whose prevalence is increasing in association with a Western lifestyle. The production of allergen-specific IgE, activation of mucosal mast cells and the recruitment and activation of effector leukocytes provides potential therapeutic targets, including selective inhibition of cytokines, adhesion molecules and signalling pathways. Blockade of IgE, using monoclonal antibodies and vaccine strategies, is a new approach for interrupting the allergic cascade, whereas the use of recombinant mutated allergens, peptides and DNA oligonucleotides will lead to improved efficacy and reduced side effects of immunotherapy to induce tolerance.<br/
    corecore